SCHEDULE 13D/A: Aspira Women's Health Secures $200,000 Convertible Note from Key Investor Jack W. Schuler Living Trust, Signaling Continued Support and Future Capital Plans

Aspira Women's Health Inc. has announced that the Jack W. Schuler Living Trust, a significant beneficial owner, purchased a $200,000 senior secured convertible note, as part of a broader capital raising strategy.

Summary

• Jack W. Schuler Living Trust, a beneficial owner, acquired a Senior Secured Convertible Note from Aspira Women's Health Inc. on March 6, 2025, with a principal amount of $200,000.
• This purchase is part of a Securities Purchase Agreement dated March 5, 2025, which allows for the sale of up to $1,500,000 in senior secured convertible notes.
• The Convertible Note matures on March 6, 2030, and accrues interest at the applicable federal rate (AFR), payable quarterly in kind and added to the principal.
• The note is convertible into 'Phase 1 Units' at a conversion price of $0.25 per unit, with each unit consisting of one share of Common Stock and a warrant to purchase 2.25 shares of Common Stock.
• The conversion price can be reduced if a subsequent financing round closes at a price lower than $0.25 per offered security, entitling the holder to additional Phase 1 Units.
• The Company has the option for mandatory conversion of the note into Phase 1 Units at $0.25 per unit if the sum of the notes and gross proceeds from a subsequent financing equals or exceeds $4 million.
• The note is secured by a first lien on the Company's Intellectual Property and blood samples, subject to any intercreditor agreements.
• The Jack W. Schuler Living Trust's beneficial ownership, including the convertible note, represents 14.7% of Aspira Women's Health Inc.'s outstanding shares, based on 17,675,022 shares outstanding as of January 27, 2025.
• The Company intends to use the net proceeds from the sale of these securities for working capital and general corporate purposes.
• Certain purchasers (NDA Investors) and those in a subsequent financing (up to $3,500,000) will collectively have the right to appoint three directors to the Company's Board for one year from the effective date of the agreement.
• NDA Investors also have the right to receive monthly performance reports and participate in management calls for one year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the capital raise provides necessary funding and signals continued investor support, the low conversion price and potential for further dilution introduce some negative aspects for existing shareholders. The secured nature of the note and governance rights for investors are positive for the new capital providers.

Positives

• The transaction provides Aspira Women's Health Inc. with additional capital for working capital and general corporate purposes, which is crucial for ongoing operations and growth.
• The investment by Jack W. Schuler Living Trust, a significant beneficial owner, demonstrates continued confidence and support from a key stakeholder.
• The note is senior secured, providing a level of security for the investor, which can be attractive for future financing rounds.
• The agreement includes provisions for certain investors to appoint directors and receive monthly reports, potentially enhancing corporate governance and oversight.

Negatives

• The conversion price of $0.25 per unit is relatively low, indicating potential significant dilution for existing shareholders upon conversion.
• The conversion price can be further reduced if a subsequent financing occurs at a lower price, increasing the potential for additional dilution.
• The Company's need to raise capital through convertible notes suggests ongoing financial requirements or a lack of sufficient internal cash flow.
• The potential for a subsequent financing of up to $3.5 million, combined with the current notes, indicates a substantial capital raise that could lead to further dilution.

Risks

• **Dilution Risk**: Conversion of the notes and warrants will increase the number of outstanding shares, potentially diluting the ownership percentage and value of existing shareholders.
• **Future Financing Risk**: The Company's ability to secure the full $1.5 million from the note offering and the subsequent $3.5 million financing is crucial for its stated use of proceeds.
• **Conversion Price Adjustment Risk**: If future financing occurs at a price lower than $0.25, the conversion price of the notes will be adjusted downwards, leading to greater dilution.
• **Operational Risks**: The document refers to 'Material Adverse Effect' in various contexts, implying general business, financial, and operational risks inherent to the Company's activities.
• **Security Interest Risk**: While the note is secured by Intellectual Property and blood samples, the value of this collateral in a default scenario is subject to market conditions and legal processes.
• **Market Volatility**: The value of the Common Stock, and thus the converted shares, is subject to market fluctuations.

Future Outlook

The Company plans to use the net proceeds from this capital raise for working capital and general corporate purposes. It also intends to file a registration statement on Form S-3 (or other appropriate form) for the resale of the securities issued under this agreement following the filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. The agreement also anticipates a 'Subsequent Financing' of up to $3,500,000.

Management Comments

• The Company's decision to enter into this agreement and other transaction documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

Industry Context

Aspira Women's Health Inc. operates in the women's health sector, focusing on diagnostic solutions. The capital raise through convertible notes is a common strategy for companies in the healthcare and biotechnology industries, which often require significant funding for research, development, and commercialization efforts. The terms of the financing, including the low conversion price and the secured nature of the note, suggest a company seeking to bolster its liquidity and potentially fund ongoing operations or strategic initiatives in a competitive and capital-intensive market.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• The purchase of the $200,000 Senior Secured Convertible Note by the Jack W. Schuler Living Trust constitutes a related party transaction, as Jack W. Schuler is a significant beneficial owner of Aspira Women's Health Inc.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to the conversion of the notes and warrants, especially if the conversion price is adjusted downwards. However, the capital infusion may stabilize the company's financial position.
• **Company**: Receives crucial capital for working capital and general corporate purposes, supporting ongoing operations and strategic initiatives. Increased oversight from significant investors through board representation and reporting requirements.
• **Creditors**: The new convertible note is senior secured, potentially impacting the recovery prospects of other unsecured creditors in a liquidation scenario, though it ranks pari passu with other unsubordinated debt.

Next Steps

• The Company is required to file a registration statement on Form S-3 (or other appropriate form) for the resale of the securities issued under this agreement following the filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2024.
• The Company may pursue a 'Subsequent Financing' to raise up to an additional $3,500,000.
• Certain purchasers (NDA Investors) will receive monthly reports detailing the Company's performance and may participate in management calls for one year from the effective date of the agreement.

Key Dates

Recommendation

Keywords

Aspira Women's Health, AWHS, Convertible Note, Securities Purchase Agreement, Jack W. Schuler, Beneficial Ownership, Capital Raise, SEC Filing, Schedule 13D, Corporate Governance, Dilution, Healthcare, Women's Health